Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
1.450
+0.020 (1.40%)
Feb 21, 2025, 4:00 PM EST - Market closed
Lexaria Bioscience Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Lexaria Bioscience stock have an average target of 9.50, with a low estimate of 7.00 and a high estimate of 12. The average target predicts an increase of 555.17% from the current stock price of 1.45.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lexaria Bioscience stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +382.76% | Jan 24, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +589.66% | Dec 2, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +589.66% | Nov 25, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +589.66% | Jul 18, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +589.66% | Jul 10, 2024 |
Financial Forecast
Revenue This Year
606.90K
from 464.28K
Increased by 30.72%
Revenue Next Year
800.19K
from 606.90K
Increased by 31.85%
EPS This Year
-0.56
from -0.47
EPS Next Year
-0.52
from -0.56
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 741,300 | 1.2M | 3.7M | ||
Avg | 606,900 | 800,190 | 2.5M | ||
Low | 474,320 | 392,000 | 1.4M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 59.7% | 102.2% | 361.6% | ||
Avg | 30.7% | 31.8% | 213.7% | ||
Low | 2.2% | -35.4% | 71.8% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -0.50 | -0.47 | -0.40 |
Avg | -0.56 | -0.52 | -0.63 |
Low | -0.59 | -0.59 | -0.84 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.